Skip to main content

Research News

Crack GPAT — Prepare for GPAT Online 
  • Drugs for Rare Diseases - New Brunswick Agreement

    The Governments of Canada and the province of New Brunswick signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest over 32 million USD over three years to improve access to new drugs for rare diseases for New Brunswick residents and to support enhanced access to existing drugs, early diagnosis, and screening for rare diseases.

  • US exits WHO, Trump signs executive order

    US withdraws from WHO after mishandling of the COVID-19 pandemic from WHO and signs executive order.

    The United States noticed its withdrawal from the World Health Organization (WHO) in 2020 due to the organization’s mishandling of the COVID-19 pandemic that arose out of Wuhan, China, and other global health crises, its failure to adopt urgently needed reforms, and its inability to demonstrate independence from the inappropriate political influence of WHO member states.

  • Florescent Probes Illuminate Cholesterol and Alzheimer’s Research
    The search for answers to Alzheimers disease and other neurodegenerative disorders remains one of the most pressing goals in brain research. Maciej J. Stawikowski, Ph.D., an assistant professor of chemistry and biochemistry at Florida Atlantic Universitys Charles E. Schmidt College of Science, believes the key may lie in understanding how cholesterol and other lipids move through cells and affect their communication.
  • Brain changes in Huntington’s disease decades before diagnosis will guide future prevention trials

    Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington’s disease, finds a new study led by UCL researchers.

  • Detecting disease with only a single molecule

    UC Riverside scientists have developed a nanopore-based tool that could help diagnose illnesses much faster and with greater precision than current tests allow, by capturing signals from individual molecules.

  • HKUMed confirms clozapine safety with first big-data evidence on rare blood cancer cases
    An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong has conducted the world’s first analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer.
  • New scan method unveils lung function secrets

    The scan method has enabled the team, led by researchers at Newcastle University, UK, to see how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant.

  • U of T researchers develop tool to fast-track measurement of protein interactions for drug discovery

    A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that revolutionizes the study of protein-protein interactions by simplifying detection while improving measurement accuracy.

  • New Drug to Prevent Migraine May Start Working Right Away
    A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. The study looked at the drug atogepant, which is a calcitonin gene-related peptide CGRP receptor antagonist taken by mouth.
  • Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

    Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important for the treatment of heart failure. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.

Subscribe to Research News